Literature DB >> 2506044

Bactericidal activity of enoxacin and lomefloxacin against Escherichia coli KL16.

C S Lewin1, S G Amyes, J T Smith.   

Abstract

Enoxacin and lomefloxacin were found to display a biphasic response when their bactericidal activities were investigated against Escherichia coli KL16 in nutrient broth. Although enoxacin required bacterial protein and RNA synthesis to exert bactericidal activity, it was able to kill non-dividing bacteria. On the other hand, the protein synthesis inhibitor chloramphenicol and the RNA synthesis inhibitor rifampicin did not abolish enoxacin's killing activity against Escherichia coli KL16 in nutrient broth. Lomefloxacin was also shown to be active against non-dividing Escherichia coli KL16.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506044     DOI: 10.1007/bf01963763

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  Pharmacokinetics and tissue penetration of orally administered lomefloxacin.

Authors:  J W Stone; J M Andrews; J P Ashby; D Griggs; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

2.  Bactericidal mechanisms of ofloxacin.

Authors:  C S Lewin; J T Smith
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

3.  Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.

Authors:  R Edwards; M Kanematsu; D Greenwood
Journal:  J Antimicrob Chemother       Date:  1988-12       Impact factor: 5.790

4.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

5.  Mechanism of action of nalidixic acid on Escherichia coli. 3. Conditions required for lethality.

Authors:  W H Deitz; T M Cook; W A Goss
Journal:  J Bacteriol       Date:  1966-02       Impact factor: 3.490

6.  Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.

Authors:  T Chang; A Black; A Dunky; R Wolf; A Sedman; J Latts; P G Welling
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

7.  Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.

Authors:  C Siporin; G Towse
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

8.  The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity.

Authors:  D S Reeves; M J Bywater; H A Holt
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

9.  4-quinolones and the SOS response.

Authors:  C S Lewin; B M Howard; N T Ratcliffe; J T Smith
Journal:  J Med Microbiol       Date:  1989-06       Impact factor: 2.472

10.  In vitro studies of S-25930 and S-25932, two new 4-quinolones.

Authors:  L J Piddock; J M Andrews; J M Diver; R Wise
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

View more
  9 in total

Review 1.  Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models.

Authors:  A Dalhoff; U Ullmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

Review 2.  The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 3.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

4.  Suppression of Reactive Oxygen Species Accumulation Accounts for Paradoxical Bacterial Survival at High Quinolone Concentration.

Authors:  Gan Luan; Yuzhi Hong; Karl Drlica; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 5.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

6.  Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.

Authors:  Muhammad Malik; Kevin R Marks; Heidi A Schwanz; Nadezhda German; Karl Drlica; Robert J Kerns
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

Review 7.  Mode of action of the new quinolones: new data.

Authors:  D C Hooper; J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

8.  Analysis of macromolecular biosynthesis to define the quinolone-induced postantibiotic effect in Escherichia coli.

Authors:  L Guan; R M Blumenthal; J C Burnham
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 9.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.